NCT07187947View on ClinicalTrials.gov

Cardiovascular Health of Transgender Individuals During the Gender-affirming Pathway

RecruitingOBSERVATIONAL
Enrollment

500

Participants

Timeline

Start Date

July 18, 2025

Primary Completion Date

December 31, 2035

Study Completion Date

December 31, 2035

Conditions
Gender IncongruenceCardiovascular (CV) RiskCardiovascular Disease Risk FactorCardiovascular Disease AcuteCardiovascular Health StatusCardiovascular Disease (CVD)Cardiovascular Disease Prevention
Interventions
DRUG

Feminizing GAHT

Before gender-affirming surgery, the regimen consists of an antiandrogen (cyproterone acetate or leuprorelin or triptorelin) plus estradiol (estradiol or estradiol valerate), whereas after an oophorectomy, estradiol/estradiol valerate can be administered alone.

DRUG

Masculinizing GAHT

Before and after gender-affirming surgery, the regimen consists of the administration of testosterone or its esters (testosterone undecanoate, testosterone enanthate)

Trial Locations (1)

40138

RECRUITING

IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola, Bologna

All Listed Sponsors
lead

IRCCS Azienda Ospedaliero-Universitaria di Bologna

OTHER